Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KA1641-ZY1
- Development stage
- Preclinical
- Lead developer
- KYINNO BIOTECHNOLOGY
- Modality
- Antibody-Based Therapeutics
01
Overview
KA1641-ZY1: sourced facts only. name: "KA1641-ZY1 had high affinity to GDF-15 (KD=0.05nM), with cross-reacting to monkey GDF15." [DOI:10.1158/1538-7445.am2023-368]; target: "KA1641-ZY1 had high affinity to GDF-15 (KD=0.05nM), with cross-reacting to monkey GDF15." [DOI:10.1158/1538-7445.am2023-368]; developer: "1Kyinno Biotechnology Co., Ltd, Beijing, China." [DOI:10.1158/1538-7445.am2023-368]; modality: "Here, we developed a humanized GDF-15 neutralizing antibody (KA1641-ZY1) with better efficacy than ponsegnomab in the pre-clinical experiments." [DOI:10.1158/1538-7445.am2023-368]; stage: "In the HT1080, Colo 205, and LS513 xenograft tumor-induced cachexia mouse models, KA1641-ZY1 restored the body weight decrease with 0.3mg/kg while ponsegnomab restored the weight with higher than 1mg/kg." [DOI:10.1158/1538-7445.am2023-368]
02
Targets
GDF15 (Growth differentiation factor 15)
Beyond the preview
Go deeper on KA1641-ZY1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KA1641-ZY1.